AACP
CRNX icon

Advantage Alpha Capital Partners’s Crinetics Pharmaceuticals CRNX Stock Holding History

Advantage Alpha Capital Partners’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-8,640
Closed -$442K – 159
2024
Q3 		$442K Buy
+8,640
New +$446K 0.1% 145

Other funds holding CRNX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Advantage Alpha Capital Partners's CRNX Position: Q4 2024 in Review

Advantage Alpha Capital Partners sold out of Crinetics Pharmaceuticals (CRNX) in Q4 2024, closing a stake of 8,640 shares — an estimated $442K sold.

Advantage Alpha Capital Partners first reported a position in CRNX in Q3 2024 and held it in 1 quarter. The position peaked at $442K in Q3 2024. 247 funds tracked by Wall St. Rank hold CRNX as of Q4 2024.

  • Advantage Alpha Capital Partners reported no remaining Crinetics Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Advantage Alpha Capital Partners sold 8,640 Crinetics Pharmaceuticals shares in Q4 2024, an estimated $442K.
  • Advantage Alpha Capital Partners first reported a position in Crinetics Pharmaceuticals in Q3 2024 and held it in 1 quarter.
  • Advantage Alpha Capital Partners's Crinetics Pharmaceuticals position peaked at $442K in Q3 2024.
  • 247 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q4 2024.

Based on Advantage Alpha Capital Partners's 13F filing for Q4 2024, filed 11 Feb 2025.